Sanofi extended the deal again last year to cover another STAT6 degrader, and, two months ago, the French pharma paid out $15 million for the rights to a once-undruggable transcription factor.

French pharmaceutical giant Sanofi is set to acquire U.S.-based Blueprint Medicines Corporation in a deal worth up to $9.5 billion, marking one of the largest European healthcare transactions of ...

France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost its position in rare immunology diseases, in the biggest deal struck by a European ...

Sanofi has agreed to acquire Blueprint Medicines for up to approximately $9.5 billion, the companies said today, in a deal designed to expand the buyer’s rare immunological disease portfolio ...

Sanofi faces setbacks after itepekimab’s Phase 3 COPD failure, removing a key growth prospect and highlighting reliance on Dupixent. Read more about why SNY is still a Buy.

PARIS (Reuters) -France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost its position in rare immunology diseases, in the biggest deal struck ...

Sanofi has been active in the M&A market this year, picking up Dren Bio’s clinical-stage bispecific antibody, DR-0201, for $600 million upfront and another $1.3 billion in milestones. Last month ...

Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease, and other ...

Sanofi SAN-0.18 % decrease; red down pointing triangle agreed to buy Blueprint Medicines BPMC 0.16 % increase; green up pointing triangle for up to $9.5 billion, the French drugmaker’s biggest ...

Sanofi’s shares fell following mixed results of its experimental drug for a deadly lung condition. Itepekimab, a medicine that is being jointly developed by Sanofi and Regeneron, is being tested ...

The cover art for 1Type's first single. (Sanofi) The song also features a spoken word interlude by Duke Al Durham, a U.K.-based poet and hip-hop artist who also has Type 1 diabetes.

Sanofi will acquire Blueprint Medicines for up to $9.5 billion, gaining Ayvakit and a promising immunology pipeline, including BLU-808 and elenestinib.